Post by thekindaguyiyam on Jun 5, 2014 15:49:58 GMT -5
Adam's BS article today was something to blame the sell off. Other posters stated that the raid was beginning as a tweet. Within 30 seconds it seemed like hugh blocks were being sold. But a 50 cent drop
for what reason? Must have been the influence of Adam Feuerstein: www.thestreet.com/story/12733760/1/the-expected-rise-and-inevitable-fall-of-mannkind.html?puc=yahoo&cm_ven=YAHOO
I like the replies best
Kathleen • 7 hours ago
You can't be serious. Afrezza is a game changer that has meaningful points of difference/advantages vs. competitors (ultra rapid acting, mimics the action of the human pancreas, significantly reduces hypos, convenient to use, no needle or refrigeration required, etc. etc.) and has a huge barrier to entry by virtue of technosphere technology. Specialists at AdCom recognized this with their nearly unaminous vote. Study participants whose lives were changed by the drug pleaded for approval. Get over your negative bias Adam and stop listening to your desperate short friends. Understand the product and the market in which it operates - which you clearly haven't taken the time to do. This one is a winner and a likely blockbuster.
12 • Reply•Share ›
Avatar
justsayin Kathleen • 4 hours ago
AT best, Afrezza makes living with diabetes less troublesome. In many ways, it's more of a lifestyle drug, while Belviq is a life-saving drug. You NEVER want to make comparisons between the two!
2 • Reply•Share ›
Avatar
Realist489 justsayin • 2 hours ago
Stop with that nonsense. Belviq is NOT a life-saving drug.
If you are obese and don't take Belviq, you can still lose weight and be fine.
If you have diabetes you NEED to take insulin. Or you will die. This is just another method of that.
An insulin drug certainly saves more lives than a weight loss drug.
2 • Reply•Share ›
Avatar
Chris_J Kathleen • 3 hours ago
Hi Kathleen, can you see my reply? Sorry I don't have a account here. I am from China looking at this stock. Can you send me at yqsl2002@gmail.com so we can talk even more? Thanks. Chris
• Reply•Share ›
Avatar
Karl Icahn • 7 hours ago
Every stock is unique, and every time is unique in the stock market. You may not know this but it is said about the stock market that the past performances are not guarantee for the future performances. Diabetese is a terrible disease far out of league in which obesity resides. Enough said.
12 • Reply•Share ›
Avatar
jderen • 7 hours ago
You keep proving your ignorance of biotech every time you open your mouth. Your blown call on the adcomm proves just how little knowledge you have in this regard. Trying to compare a mediocre weight loss drug which was restricted from use in obese patients with a drug that can eliminate needles for many diabetics and vastly improve treatment adherence for all diabetics is lunacy. The key here is that afrezza will be approved which will validate the technosphere/ dreamboat platform. This will lead to partnership with big pharma and will produce long lasting revenue stream with nearly unlimited earnings potential. Afrezza is just the tip of the iceberg. It's only a means to the end of technosphere validation. The new delivery method is the golden goose. Afrezza is just one potential golden egg.
9 • Reply•Share ›
Avatar
justsayin jderen • 4 hours ago
That "mediocre" drug can save thousands of lives annually, can Alfeeza? BTW, where in the world did you hear that Belviq was restricted from use in the obese? That's the primary purpose and success of Belviq for god's sake!!
2 • Reply•Share ›
Avatar
theeseer • 6 hours ago
The rise and fall of Fuerstein and Cramer has also been inevitable. Cramer started on radio and TV as an advocate for the small "home gamer" and had his producer call me and others to call him on a specific topic. In my case they contacted me twice. (And i can prove it)The first time they asked me to call in with a stock in the GPS field and I called in and was the first to offer Garmin which Cramer rejected in favor of Navteq and then the following week took credit for Garmin. Not that I care but it showed me how he operates. Next he made a video which you can find on you tube describing how "others" sent out false rumors to manipulate the Market. Along that road he opens the "Street" and hires Fuerstein who has zero scientific or medical credentials to watch the Pharma market. Fuerstein in yet another in a series of "hit" pieces on MNKD now makes ridiculous comparisons of wildly different medical companies based on technical analysis after having to apologize for his failure on his ADCOM outcome call for MNKD which probably costthe average guy a ton of money. So Cramer with all time low ratings on his CNBC show and a pathetic track record overall and hiring unqualified analysts is definitely on his way out and it can't come too soon to protect the "home gamer" from such shoddy posts, personnel and money losing advice.
13 • Reply•Share ›
Avatar
forfund • 7 hours ago
Completely wrong comparison for two totally different drugs.
Completely wrong prescription for the shorts
5 • Reply•Share ›
Avatar
stewie • 7 hours ago
adam fraudsteen and his masters are in a panic over these SHORT POSITIONS
especially ARNA ZERO SELLERS NONE NADA
\
rot in hell AF AND ROT SLOWLY
5 • Reply•Share ›
Avatar
surfish • 6 hours ago
Wishful thinking, AF.
3 • Reply•Share ›
Avatar
Mike • 3 hours ago
I don't know this writer, but comparing ARNA and MNKD IS NOT A GOOD COMPARISON. No real facts on MNKD shows he is a lazy writer.
2 • Reply•Share ›
Avatar
Amy • 6 hours ago
Adam, didn't you say that you were wrong at the end of the ADCOM meeting? Didn't Cramer say that he did NOT KNOW much about MNKD and therefore he would not comment on it?
2 • Reply•Share ›
Avatar
Nicholas Vernola Amy • 5 hours ago
Cramer responds that way when he holds it
3 • Reply•Share ›
Avatar
Allen • 6 hours ago
If an investor's plan is to be short, then you'll be short post-approval. Make some quick cash, get out, because that's all you want out of the stock. But AFREZZA - and looking further down the line, the delivery system which will be conformed to delivery other drugs that now require an injection - is a LONG play for patient, smart investors. I hope you are right that the sell-off starts after approval that way I can once again buy cheap thanks to the panic induced by one of your articles. Keep up the good work!
2 • Reply•Share ›
Avatar
buggyfunbunny • 7 hours ago
But... once every diabetic in the world is on Afrezza (and they will be), the pastry shops on Hanover will be printing money.
2 • Reply•Share ›
Avatar
This comment is awaiting moderation. Show comment.
Avatar
stewie WeThePeople • 5 hours ago
11.11
1 • Reply•Share ›
Avatar
WCoastGuynCA • 7 hours ago
Mannkind is tremendously risky at its current share price with two previous rejections of Afrezza and not knowing what the F.D.A. will decide this time.
A better investment with substantial upside is Amarantus Bioscience - AMBS - which is currently trading under a dime.
The company will be launching first diagnostic blood test, LymPro,to detect early stage Alzheimer's this year. Partnership to be announced soon.
The company's pateneted drug, MANF, already has three orphan indications. It could be worth billions of dollars.
Twitter: @amarantusbio .... 9,997 followers.
2 • Reply•Share ›
Avatar
JC WCoastGuynCA • 7 hours ago
You are promoting a penny stock over a stock going into FDA decision with a 27-1 Adcom approval? Also the dreamboat technology has uses other than for Afrezza, Al Mann has sold his devices to Medtronic before, after all he is a billionaire.
12 • Reply•Share ›
Avatar
Nicholas Vernola JC • 5 hours ago
what drug approved is he taking?
• Reply•Share ›
Avatar
Mike WCoastGuynCA • 3 hours ago
Do your homework, it's been 3 rejections.... AMBS is junk also.
• Reply•Share ›
Avatar
Sewell Whitney • 3 hours ago
Unique product. Unique delivery system. Unique opportunity for a major drug company to buy them out. At a premium. Cramer is a momentum player who whines when he misses the boat and blows hard the rest of the time.
1 • Reply•Share ›
Avatar
Chris_J Sewell Whitney • 2 hours ago
Hi Sewell, if you can see this reply can you write me an email at yqsl2002@gmail.com I'm in China. Here we have 100 million diabetic patients. I really want to have good exchange with professional in America. Thanks. Chris
• Reply•Share ›
Avatar
Nicholas Vernola • 6 hours ago
The similarities of stocks he uses as an example , are in actuality poor examples. Insulin market exists, insulin is not an elective therapy unless immediate death is your goal. Alfreeza is not a me too opportunity, it's a one of a kind. In order for a sell off upon approval, new sales would. Have to Not materialize. A 70 billion dollar market, a unique application that offers unprecedented convenience to patients for the first time, improves the life exponentially of afflicted population. So that being said, new sales in the millions if not billions, and the stock does not sell on a multiple of its earnings? I'm glad I don't listen to people who write these things, if they made money in the market, they wouldn't be writing.
1 • Reply•Share ›
Avatar
Chris_J Nicholas Vernola • 2 hours ago
Hi Nicolas, can you see this reply? Would you like to write me an email at yqsl2002@gmail.com I'm in China. You know we have 100 million diabetic patients. I am looking for really good conversation with professional in America about this drug and company. Thanks. Chris
• Reply•Share ›
Avatar
hon788 • 4 hours ago
Yes many are freaked out by the massive drop on arna after the approval, its still seems unreal.
1 • Reply•Share ›
Avatar
This comment is awaiting moderation. Show comment.
Avatar
justsayin TheTruth • 4 hours ago
Obesity is the second-leading cause of death in the U.S., but "very few people need obesity pills"? There's about a 50% chance that you need them. Wait, let me flip a coin.
1 • Reply•Share ›
Avatar
Realist489 justsayin • 2 hours ago
"There's about a 50% chance that you need them."
I would love to hear the source for this?
And the reason diabetes doesn't kill is BECAUSE PEOPLE TAKE INSULIN. If a person with diabetes stops taking insulin they will die much quicker than an obese person.
The fact you don't see that is what makes your conclusion incorrect.
for what reason? Must have been the influence of Adam Feuerstein: www.thestreet.com/story/12733760/1/the-expected-rise-and-inevitable-fall-of-mannkind.html?puc=yahoo&cm_ven=YAHOO
I like the replies best
Kathleen • 7 hours ago
You can't be serious. Afrezza is a game changer that has meaningful points of difference/advantages vs. competitors (ultra rapid acting, mimics the action of the human pancreas, significantly reduces hypos, convenient to use, no needle or refrigeration required, etc. etc.) and has a huge barrier to entry by virtue of technosphere technology. Specialists at AdCom recognized this with their nearly unaminous vote. Study participants whose lives were changed by the drug pleaded for approval. Get over your negative bias Adam and stop listening to your desperate short friends. Understand the product and the market in which it operates - which you clearly haven't taken the time to do. This one is a winner and a likely blockbuster.
12 • Reply•Share ›
Avatar
justsayin Kathleen • 4 hours ago
AT best, Afrezza makes living with diabetes less troublesome. In many ways, it's more of a lifestyle drug, while Belviq is a life-saving drug. You NEVER want to make comparisons between the two!
2 • Reply•Share ›
Avatar
Realist489 justsayin • 2 hours ago
Stop with that nonsense. Belviq is NOT a life-saving drug.
If you are obese and don't take Belviq, you can still lose weight and be fine.
If you have diabetes you NEED to take insulin. Or you will die. This is just another method of that.
An insulin drug certainly saves more lives than a weight loss drug.
2 • Reply•Share ›
Avatar
Chris_J Kathleen • 3 hours ago
Hi Kathleen, can you see my reply? Sorry I don't have a account here. I am from China looking at this stock. Can you send me at yqsl2002@gmail.com so we can talk even more? Thanks. Chris
• Reply•Share ›
Avatar
Karl Icahn • 7 hours ago
Every stock is unique, and every time is unique in the stock market. You may not know this but it is said about the stock market that the past performances are not guarantee for the future performances. Diabetese is a terrible disease far out of league in which obesity resides. Enough said.
12 • Reply•Share ›
Avatar
jderen • 7 hours ago
You keep proving your ignorance of biotech every time you open your mouth. Your blown call on the adcomm proves just how little knowledge you have in this regard. Trying to compare a mediocre weight loss drug which was restricted from use in obese patients with a drug that can eliminate needles for many diabetics and vastly improve treatment adherence for all diabetics is lunacy. The key here is that afrezza will be approved which will validate the technosphere/ dreamboat platform. This will lead to partnership with big pharma and will produce long lasting revenue stream with nearly unlimited earnings potential. Afrezza is just the tip of the iceberg. It's only a means to the end of technosphere validation. The new delivery method is the golden goose. Afrezza is just one potential golden egg.
9 • Reply•Share ›
Avatar
justsayin jderen • 4 hours ago
That "mediocre" drug can save thousands of lives annually, can Alfeeza? BTW, where in the world did you hear that Belviq was restricted from use in the obese? That's the primary purpose and success of Belviq for god's sake!!
2 • Reply•Share ›
Avatar
theeseer • 6 hours ago
The rise and fall of Fuerstein and Cramer has also been inevitable. Cramer started on radio and TV as an advocate for the small "home gamer" and had his producer call me and others to call him on a specific topic. In my case they contacted me twice. (And i can prove it)The first time they asked me to call in with a stock in the GPS field and I called in and was the first to offer Garmin which Cramer rejected in favor of Navteq and then the following week took credit for Garmin. Not that I care but it showed me how he operates. Next he made a video which you can find on you tube describing how "others" sent out false rumors to manipulate the Market. Along that road he opens the "Street" and hires Fuerstein who has zero scientific or medical credentials to watch the Pharma market. Fuerstein in yet another in a series of "hit" pieces on MNKD now makes ridiculous comparisons of wildly different medical companies based on technical analysis after having to apologize for his failure on his ADCOM outcome call for MNKD which probably costthe average guy a ton of money. So Cramer with all time low ratings on his CNBC show and a pathetic track record overall and hiring unqualified analysts is definitely on his way out and it can't come too soon to protect the "home gamer" from such shoddy posts, personnel and money losing advice.
13 • Reply•Share ›
Avatar
forfund • 7 hours ago
Completely wrong comparison for two totally different drugs.
Completely wrong prescription for the shorts
5 • Reply•Share ›
Avatar
stewie • 7 hours ago
adam fraudsteen and his masters are in a panic over these SHORT POSITIONS
especially ARNA ZERO SELLERS NONE NADA
\
rot in hell AF AND ROT SLOWLY
5 • Reply•Share ›
Avatar
surfish • 6 hours ago
Wishful thinking, AF.
3 • Reply•Share ›
Avatar
Mike • 3 hours ago
I don't know this writer, but comparing ARNA and MNKD IS NOT A GOOD COMPARISON. No real facts on MNKD shows he is a lazy writer.
2 • Reply•Share ›
Avatar
Amy • 6 hours ago
Adam, didn't you say that you were wrong at the end of the ADCOM meeting? Didn't Cramer say that he did NOT KNOW much about MNKD and therefore he would not comment on it?
2 • Reply•Share ›
Avatar
Nicholas Vernola Amy • 5 hours ago
Cramer responds that way when he holds it
3 • Reply•Share ›
Avatar
Allen • 6 hours ago
If an investor's plan is to be short, then you'll be short post-approval. Make some quick cash, get out, because that's all you want out of the stock. But AFREZZA - and looking further down the line, the delivery system which will be conformed to delivery other drugs that now require an injection - is a LONG play for patient, smart investors. I hope you are right that the sell-off starts after approval that way I can once again buy cheap thanks to the panic induced by one of your articles. Keep up the good work!
2 • Reply•Share ›
Avatar
buggyfunbunny • 7 hours ago
But... once every diabetic in the world is on Afrezza (and they will be), the pastry shops on Hanover will be printing money.
2 • Reply•Share ›
Avatar
This comment is awaiting moderation. Show comment.
Avatar
stewie WeThePeople • 5 hours ago
11.11
1 • Reply•Share ›
Avatar
WCoastGuynCA • 7 hours ago
Mannkind is tremendously risky at its current share price with two previous rejections of Afrezza and not knowing what the F.D.A. will decide this time.
A better investment with substantial upside is Amarantus Bioscience - AMBS - which is currently trading under a dime.
The company will be launching first diagnostic blood test, LymPro,to detect early stage Alzheimer's this year. Partnership to be announced soon.
The company's pateneted drug, MANF, already has three orphan indications. It could be worth billions of dollars.
Twitter: @amarantusbio .... 9,997 followers.
2 • Reply•Share ›
Avatar
JC WCoastGuynCA • 7 hours ago
You are promoting a penny stock over a stock going into FDA decision with a 27-1 Adcom approval? Also the dreamboat technology has uses other than for Afrezza, Al Mann has sold his devices to Medtronic before, after all he is a billionaire.
12 • Reply•Share ›
Avatar
Nicholas Vernola JC • 5 hours ago
what drug approved is he taking?
• Reply•Share ›
Avatar
Mike WCoastGuynCA • 3 hours ago
Do your homework, it's been 3 rejections.... AMBS is junk also.
• Reply•Share ›
Avatar
Sewell Whitney • 3 hours ago
Unique product. Unique delivery system. Unique opportunity for a major drug company to buy them out. At a premium. Cramer is a momentum player who whines when he misses the boat and blows hard the rest of the time.
1 • Reply•Share ›
Avatar
Chris_J Sewell Whitney • 2 hours ago
Hi Sewell, if you can see this reply can you write me an email at yqsl2002@gmail.com I'm in China. Here we have 100 million diabetic patients. I really want to have good exchange with professional in America. Thanks. Chris
• Reply•Share ›
Avatar
Nicholas Vernola • 6 hours ago
The similarities of stocks he uses as an example , are in actuality poor examples. Insulin market exists, insulin is not an elective therapy unless immediate death is your goal. Alfreeza is not a me too opportunity, it's a one of a kind. In order for a sell off upon approval, new sales would. Have to Not materialize. A 70 billion dollar market, a unique application that offers unprecedented convenience to patients for the first time, improves the life exponentially of afflicted population. So that being said, new sales in the millions if not billions, and the stock does not sell on a multiple of its earnings? I'm glad I don't listen to people who write these things, if they made money in the market, they wouldn't be writing.
1 • Reply•Share ›
Avatar
Chris_J Nicholas Vernola • 2 hours ago
Hi Nicolas, can you see this reply? Would you like to write me an email at yqsl2002@gmail.com I'm in China. You know we have 100 million diabetic patients. I am looking for really good conversation with professional in America about this drug and company. Thanks. Chris
• Reply•Share ›
Avatar
hon788 • 4 hours ago
Yes many are freaked out by the massive drop on arna after the approval, its still seems unreal.
1 • Reply•Share ›
Avatar
This comment is awaiting moderation. Show comment.
Avatar
justsayin TheTruth • 4 hours ago
Obesity is the second-leading cause of death in the U.S., but "very few people need obesity pills"? There's about a 50% chance that you need them. Wait, let me flip a coin.
1 • Reply•Share ›
Avatar
Realist489 justsayin • 2 hours ago
"There's about a 50% chance that you need them."
I would love to hear the source for this?
And the reason diabetes doesn't kill is BECAUSE PEOPLE TAKE INSULIN. If a person with diabetes stops taking insulin they will die much quicker than an obese person.
The fact you don't see that is what makes your conclusion incorrect.
